Lilly shuffles marketing personnel

Share this article:
Lilly shuffles marketing personnel
Lilly shuffles marketing personnel
Eli Lilly will consolidate its global and international marketing organizations as the drugmaker undergoes a companywide initiative to reduce management layers.

Under the plan, Dan Hasler, former VP of global brands, will assume the role of VP of the newly formed marketing organization, Lilly said in a statement issued today.

Exiting Lilly is Rich Pilnik, former VP and chief marketing officer.

Pilnik retires following a 25 year career with the Indianapolis-based drugmaker. He twice served as the company's chief marketing officer--from 1998 to 2001 and from 2006 to present--and also recently served as president of Lilly Europe.

Meanwhile, Nancy Lilly, former VP of US sales and marketing for specialty products, has been named VP of new product planning and market analytics.

These executive level changes are effective immediately, Lilly said, with the new structure to be fully in place by July 1.

“These leadership changes will help to strengthen key aspects of Lilly's operations as we also develop the next generation of leadership for the company,” CEO John Lechleiter said in a statement.

Lechleiter today also called for changes to Lilly's R&D, international operations and US operations divisions.

Further details can be found by logging on to: http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=311669.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...